Bragazzi NL, Zhong W, Shu J, Abu Much A, Lotan D, Grupper A et al. Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017. European Journal of Preventive Cardiology. 2021;zwaa147..
DOI: 10.1093/eurjpc/zwaa147

Терещенко С.Н. Галявич А.С., Ускач Т.М., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л. и др. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):311-74.
DOI: 10.15829/1560-4071-2020-4083

Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart (British Cardiac Society). 2002;87(3):235–41.
DOI: 10.1136/heart.87.3.235

Mamas MA, Sperrin M, Watson MC, Coutts A, Wilde K, Burton C et al. Do patients have worse outcomes in heart failure than in cancer? A primary care-based cohort study with 10-year follow-up in Scotland. European Journal of Heart Failure. 2017;19(9):1095–104.
DOI: 10.1002/ejhf.822

Dunlay SM, Redfield MM, Weston SA, Therneau TM, Hall Long K, Shah ND et al. Hospitalizations After Heart Failure Diagnosis. Journal of the American College of Cardiology. 2009;54(18):1695–702.
DOI: 10.1016/j.jacc.2009.08.019

Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta‐analysis. European Journal of Heart Failure. 2019;21(11):1306–25.
DOI: 10.1002/ejhf.1594

Поляков Д.C., Фомин И.В., Беленков Ю.Н., Мареев В.Ю., Агеев Ф.Т., Артемьева Е.Г. и др. Хроническая сердечная недостаточность в Российской Федерации: что изменилось за 20 лет наблюдения? Результаты исследования ЭПОХА–ХСН. Кардиология. 2021;61(4):4-14.
DOI: 10.18087/cardio.2021.4.n1628

Pocock SJ, Ariti CA, McMurray JJV, Maggioni A, Køber L, Squire IB et al. Predicting survival in heart failure: a risk score based on 39 372 patients from 30 studies. European Heart Journal. 2013;34(19):1404– 13.
DOI: 10.1093/eurheartj/ehs337

Lawson CA, Zaccardi F, Squire I, Ling S, Davies MJ, Lam CSP et al. 20-year trends in cause-specific heart failure outcomes by sex, socioeconomic status, and place of diagnosis: a population-based study. The Lancet Public Health. 2019;4(8):e406–20.
DOI: 10.1016/S24682667(19)30108-2

Butler J, Yang M, Manzi MA, Hess GP, Patel MJ, Rhodes T et al. Clinical Course of Patients with Worsening Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology. 2019;73(8):935–44.
DOI: 10.1016/j.jacc.2018.11.049

Hollenberg SM, Warner Stevenson L, Ahmad T, Amin VJ, Bozkurt B, Butler J et al. 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized with Heart Failure. Journal of the American College of Cardiology. 2019;74(15):1966–2011.
DOI: 10.1016/j.jacc.2019.08.001

Мареев В.Ю., Агеев Ф.Т., Арутюнов Г.П., Коротеев А.В., Мареев Ю.В., Овчинников А.Г. и др. Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Утверждены на Конгрессе ОССН 7 декабря 2012 года, на Правлении ОССН 31 марта 2013 и Конгрессе РКО 25 сентября 2013 года. Журнал Сердечная Недостаточность. 2013;14(7):379-472.

Hall MJ, Levant S, DeFrances CJ. Hospitalization for congestive heart failure: United States, 2000-2010. NCHS data brief. 2012;108:1–8

Johansen H, Strauss B, Arnold JMO, Moe G, Liu P. On the rise: The current and projected future burden of congestive heart failure hospitalization in Canada. The Canadian Journal of Cardiology. 2003;19(4):430–5

Sayago-Silva I, García-López F, Segovia-Cubero J. Epidemiology of Heart Failure in Spain Over the Last 20 Years. Revista Española de Cardiología (English Edition). 2013;66(8):649–56.
DOI: 10.1016/j.rec.2013.03.012

Sierpiński R, Sokolska JM, Suchocki T, Koń B, Urbański F, Kruk M et al. 10 year trends in hospitalization rates due to heart failure and related in‐hospital mortality in Poland (2010–2019). ESC Heart Failure. 2020;7(6):3365–73.
DOI: 10.1002/ehf2.13060

Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalizations and Readmissions From 2010 to 2017. JAMA Cardiology. 2021;6(8):952.
DOI: 10.1001/jamacardio.2020.7472

National Guideline Centre (Great Britain), National Institute for Health and Care Excellence (Great Britain). Chronic heart failure in adults: diagnosis and management. -London: National Institute for Health and Care Excellence (UK);2018. ISBN 978-1-4731-3093-7

Мареев В.Ю., Фомин И.В., Агеев Ф.Т., Арутюнов Г.П., Беграмбекова Ю.Л., Беленков Ю.Н. и др. Клинические рекомендации. Хроническая сердечная недостаточность (ХСН). Журнал Сердечная Недостаточность. 2017;18(1):3–40.
DOI: 10.18087/rhfj.2017.1.2346

Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. The Lancet. 2018;391(10120):572–80.
DOI: 10.1016/S0140-6736(17)32520-5

Greene SJ, Mentz RJ, Felker GM. Outpatient Worsening Heart Failure as a Target for Therapy: A Review. JAMA Cardiology. 2018;3(3):252– 9.
DOI: 10.1001/jamacardio.2017.5250

Koudstaal S, Pujades-Rodriguez M, Denaxas S, Gho JMIH, Shah AD, Yu N et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. European Journal of Heart Failure. 2017;19(9):1119–27.
DOI: 10.1002/ejhf.709

Bello NA, Claggett B, Desai AS, McMurray JJV, Granger CB, Yusuf S et al. Influence of Previous Heart Failure Hospitalization on Cardiovascular Events in Patients with Reduced and Preserved Ejection Fraction. Circulation: Heart Failure. 2014;7(4):590–5.
DOI: 10.1161/CIRCHEARTFAILURE.113.001281

Solomon SD, Claggett B, Packer M, Desai A, Zile MR, Swedberg K et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: The PARADIGM-HF Trial. JACC. Heart failure. 2016;4(10):816–22.
DOI: 10.1016/j.jchf.2016.05.002

Solomon SD, Dobson J, Pocock S, Skali H, McMurray JJV, Granger CB et al. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation. 2007;116(13):1482–7.
DOI: 10.1161/CIRCULATIONAHA.107.696906

Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., Рылова А.К., Пашкевич Д.Д., Витер К.В. и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55(5):12-21

Поляков Д.С., Фомин И.В., Валикулова Ф.Ю., Вайсберг А.Р., Краием Н., Бадин Ю.В. и др. Эпидемиологическая программа ЭПОХА-ХСН: Декомпенсация хронической сердечной недостаточности в реальной клинической практике (ЭПОХА–Д– ХСН). Журнал Сердечная Недостаточность. 2016;17(5):299–305.
DOI: 10.18087/rhfj.2016.5.2239

Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. American Heart Journal. 2007;154(2):260–6.
DOI: 10.1016/j.ahj.2007.01.041

Hamo CE, Butler J, Gheorghiade M, Chioncel O. The bumpy road to drug development for acute heart failure. European Heart Journal Supplements. 2016;18(Suppl G):G19–32.
DOI: 10.1093/eurheartj/suw045

Bhagat AA, Greene SJ, Vaduganathan M, Fonarow GC, Butler J. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization. JACC: Heart Failure. 2019;7(1):1–12.
DOI: 10.1016/j.jchf.2018.06.011

Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K et al. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. New England Journal of Medicine. 2019;380(6):539–48.
DOI: 10.1056/NEJMoa1812851

DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H et al. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial. JAMA Cardiology. 2020;5(2):202–7.
DOI: 10.1001/jamacardio.2019.4665

Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐ AHF). European Journal of Heart Failure. 2020;22(4):713– 22.
DOI: 10.1002/ejhf.1713

Greene SJ, Butler J, Fonarow GC. Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure – Optimizing Therapy With the Need for Speed. JAMA Cardiology. 2021;6(7):743–4.
DOI: 10.1001/jamacardio.2021.0496

Ouwerkerk W, Voors AA, Anker SD, Cleland JG, Dickstein K, Filippatos G et al. Determinants and clinical outcome of uptitration of ACEinhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal. 2017;38(24):1883–90.
DOI: 10.1093/eurheartj/ehx026

Vaduganathan M, Claggett BL, Jhund PS, Cunningham JW, Pedro Ferreira J, Zannad F et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. The Lancet. 2020;396(10244):121–8.
DOI: 10.1016/S0140-6736(20)30748-0

Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J et al. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT‐proBNP and GDF‐15, of Heart Failure therapies (STRONGHF): rationale and design for a multicentre, randomized, parallelgroup study. European Journal of Heart Failure. 2019;21(11):1459–67.
DOI: 10.1002/ejhf.1575

Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR et al. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). European Journal of Heart Failure. 2021;23(9):1499–511.
DOI: 10.1002/ejhf.2271

Фомин И.В., Краием Н., Поляков Д.С., Виноградова Н.Г., Валикулова Ф.Ю., Вайсберг А.Р., Щербинина Е.В. Понятие стабильности течения ХСН-приемлемо ли оно для Российской практики? Кардиология. 2018;58(S3):55-63.
DOI: 10.18087/cardio.2356

Лопатин Ю.М., Недогода С.В., Архипов М.В., Галявич А.С., Козиолова Н.А., Ложкина Н.Г. и др. Фармакоэпидемиологический анализ рутинной практики ведения пациентов с хронической сердечной недостаточностью в Российской Федерации. Часть I. Российский кардиологический журнал. 2021;26(4):93-102.
DOI: 10.15829/1560-4071-2021-4368

Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, Martinez FA et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. The Lancet. 2009;374(9704):1840–8.
DOI: 10.1016/S0140-6736(09)61913-9

Packer M, Poole-Wilson PA, Armstrong PW, Cleland JG, Horowitz JD, Massie BM et al. Comparative effects of low and high doses of the angiotensinconverting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation. 1999;100(23):2312–8.
DOI: 10.1161/01.cir.100.23.2312

Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS et al. Physicians’ guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure. 2017;19(11):1414–23.
DOI: 10.1002/ejhf.887

Turgeon RD, Kolber MR, Loewen P, Ellis U, McCormack JP. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and m eta-analysis. PLOS ONE. 2019;14(2):e0212907.
DOI: 10.1371/journal.pone.0212907

Srivastava PK, DeVore AD, Hellkamp AS, Thomas L, Albert NM, Butler J et al. Heart Failure Hospitalization and Guideline-Directed Prescribing Patterns Among Heart Failure with Reduced Ejection Fraction Patients. JACC: Heart Failure. 2021;9(1):28–38.
DOI: 10.1016/j.jchf.2020.08.017

Fonseca C, Brito D, Branco P, Frazão JM, Silva-Cardoso J, Bettencourt P. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Revista Portuguesa de Cardiologia. 2020;39(9):517–41.
DOI: 10.1016/j.repc.2020.03.015

Rakisheva A, Marketou M, Klimenko A, Troyanova‐Shchutskaia T, Vardas P. Hyperkalemia in heart failure: Foe or friend? Clinical Cardiology. 2020;43(7):666–75.
DOI: 10.1002/clc.23392

Rossignol P, Lainscak M, Crespo‐Leiro MG, Laroche C, Piepoli MF, Filippatos G et al. Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long‐Term Registry. European Journal of Heart Failure. 2020;22(8):1378–89.
DOI: 10.1002/ejhf.1793

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized with Acute Decompensated Heart Failure: A Report From the ADHERE Database. Journal of Cardiac Failure. 2007;13(6):422–30.
DOI: 10.1016/j.cardfail.2007.03.011

Powell C, Kavanagh K, Morgan J, Stakelum Byrne N, Keelan P, Murphy N. 49 Eligibility for dapagliflozin in a real–life heart failure clinic. A32.1-A32. Irish Cardiac Society Annual Scientific Meeting & AGM (Virtual), October 1st – 3rd 2020. BMJ Publishing Group Ltd and British Cardiovascular Society. 2020.
DOI: 10.1136/heartjnl-2020ICS.49.

Maltês S, Cunha GJL, Rocha BML, Presume J, Guerreiro R, Henriques C et al. Dapagliflozin in a Real-World Chronic Heart Failure Population: How Many Are Actually Eligible? Cardiology. 2021;146(2):201–6.
DOI: 10.1159/000512432

Mewton N, Girerd N, Boffa J-J, Courivaud C, Isnard R, Juillard L et al. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. Archives of Cardiovascular Diseases. 2020;113(10):660–70.
DOI: 10.1016/j.acvd.2020.03.018

Cautela J, Tartiere J, Cohen-Solal A, Bellemain‐Appaix A, Theron A, Tibi T et al. Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients. European Journal of Heart Failure. 2020;22(8):1357–65.
DOI: 10.1002/ejhf.1835

Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC et al. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. JACC: Heart Failure. 2019;7(4):350–8.
DOI: 10.1016/j.jchf.2018.11.011

Teramoto K, Tromp J, Lam CSP. Heart failure or heart success? Cardiovascular Research. 2021;117(3):e29–34.
DOI: 10.1093/cvr/cvab022

Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. New England Journal of Medicine. 2021;384(2):105–16.
DOI: 10.1056/NEJMoa2025797

Teerlink JR, Diaz R, Felker GM, McMurray JJV, Metra M, Solomon SD et al. Effect of Ejection Fraction on Clinical Outcomes in Patients Treated with Omecamtiv Mecarbil in GALACTIC-HF. Journal of the American College of Cardiology. 2021;78(2):97–108.
DOI: 10.1016/j.jacc.2021.04.065

Emdin M, Aimo A, Castiglione V, Vergaro G, Georgiopoulos G, Saccaro LF et al. Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure. Journal of the American College of Cardiology. 2020;76(15):1795–807.
DOI: 10.1016/j.jacc.2020.08.031

Armstrong PW, Pieske B, Anstrom KJ, Ezekowitz J, Hernandez AF, Butler J et al. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine. 2020;382(20):1883–93.
DOI: 10.1056/NEJMoa1915928

Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80– 98.
DOI: 10.1161/CIRCULATIONAHA.118.030099

Ponikowski P, Kirwan B-A, Anker SD, McDonagh T, Dorobantu M, Drozdz J et al. Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet (London, England). 2020;396(10266):1895–904.
DOI: 10.1016/S0140-6736(20)32339-4

Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. The New England Journal of Medicine. 2021;384(2):117–28.
DOI: 10.1056/NEJMoa2030183

Шляхто Е.В., Звартау Н.Э., Виллевальде С.В., Яковлев А.Н., Соловьева А.Е., Алиева А.С. и др. Система управления сердечнососудистыми рисками: предпосылки к созданию, принципы организации, таргетные группы. Российский кардиологический журнал. 2019;24(11):69–82.
DOI: 10.15829/1560-4071-2019-1169-82

Шляхто Е.В., Звартау Н.Э., Виллевальде С.В., Яковлев А.Н., Соловьева А.Е., Авдонина Н.Г. и др. Реализованные модели и элементы организации медицинской помощи пациентам с сердечной недостаточностью в регионах Российской Федерации: перспективы трансформации в региональные системы управления сердечно-сосудистыми рисками. Российский кардиологический журнал. 2020;25(4):9-18.
DOI: 10.15829/1560-4071-2020-4-3792

Hernandez AF. Relationship Between Early Physician Follow-up and 30-Day Readmission Among Medicare Beneficiaries Hospitalized for Heart Failure. JAMA. 2010;303(17):1716.
DOI: 10.1001/jama.2010.533

McMurray JJV, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaborati. European Journal of Heart Failure. 2012;14(8):803–69.
DOI: 10.1093/eurjhf/hfs105

Samsky MD, Lin L, Greene SJ, Lippmann SJ, Peterson PN, Heidenreich PA et al. Patient Perceptions and Familiarity with Medical Therapy for Heart Failure. JAMA Cardiology. 2020;5(3):292–9.
DOI: 10.1001/jamacardio.2019.4987

Мареев В.Ю., Беграмбекова Ю.Л., Даниелян М.О., Агеев Ф.Т., Гиляревский С.Р., Беленков Ю.Н. и др. Какие вопросы задаются и на какие вопросы способны ответить исследования по немедикаментозному лечению пациентов с сердечной недостаточностью. Уроки исследования ШАНС. Журнал Сердечная Недостаточность. 2014;15(6):383-96.

Ситникова М.Ю., Лясникова Е.А., Юрченко А.В., Трукшина М.А., Куулар А.А., Галенко В.Л. и др. Результаты 3 лет работы Российского госпитального регистра хронической сердечной недостаточности (Russian hoSpital Heart Failure Registry RUS-HFR): взаимосвязь менеджмента и исходов у больных хронической сердечной недостаточностью. Кардиология. 2018;58(10S):9-19.
DOI: 10.18087/cardio.2483

Allen LA, Venechuk G, McIlvennan CK, Page RL, Knoepke CE, Helmkamp LJ et al. An Electronically Delivered Patient-Activation Tool for Intensification of Medications for Chronic Heart Failure with Reduced Ejection Fraction: The EPIC-HF Trial. Circulation. 2021;143(5):427–37.
DOI: 10.1161/CIRCULATIONAHA.120.051863

Unlu O, Levitan EB, Reshetnyak E, Kneifati-Hayek J, Diaz I, Archambault A et al. Polypharmacy in Older Adults Hospitalized for Heart Failure. Circulation: Heart Failure. 2020;13(11):e006977.
DOI: 10.1161/CIRCHEARTFAILURE.120.006977

Соловьева А.Е., Яковлев А.Н., Виллевальде С.В., Звартау Н.Э., Шляхто Е.В. Льготное лекарственное обеспечение пациентов высокого сердечнососудистого риска как важный компонент достижения национальных целей. Вестник Росздравнадзора. 2019;4:20-7.
DOI: 10.35576/article_5d651dbc201140.18252870

Van Spall HGC, Rahman T, Mytton O, Ramasundarahettige C, Ibrahim Q, Kabali C et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. European Journal of Heart Failure. 2017;19(11):1427–43.
DOI: 10.1002/ejhf.765

Li Y, Fu MR, Luo B, Li M, Zheng H, Fang J. The Effectiveness of Transitional Care Interventions on Health Care Utilization in Patients Discharged From the Hospital With Heart Failure: A Systematic Review and Meta-Analysis. Journal of the American Medical Directors Association. 2021;22(3):621–9.
DOI: 10.1016/j.jamda.2020.09.019

Виллевальде C.В., Соловьева А.Е., Звартау Н.Э., Авдонина Н. Г., Яковлев А. Н., Ситникова М. Ю., и др. Принципы организации медицинской помощи пациентам с сердечной недостаточностью в системе управления сердечно-сосудистыми рисками: фокус на преемственность и маршрутизацию пациентов. Практические материалы. Российский кардиологический журнал. 2021;26(S3):102-41.
DOI: 10.15829/1560-4071-2021-4558